Emerging Dolutegravir Resistance Among Children on Antiretroviral Therapy With Virological Failure in Malawi: Results From a 2023 National Cross‐Sectional Survey
Journal of the International AIDS Society · 2026
DOI: 10.1002/jia2.70108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the International AIDS Society, 2026. Verfasst von George Bello und 25 weiteren Autor:innen. Beteiligte Einrichtung: Public Health Institute of Malawi, Ministry of Health, Lilongwe, Malawi. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Piperazines, Oxazines, Pyridones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CDC HHS, Centers for Disease Control and Prevention.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Malawi began transitioning children living with HIV (CLHIV) to dolutegravir‐based regimens (DBRs) in 2020, and 99.9% were on a DBR by September 2023. With nearly universal use of DBR, surveillance of HIV drug resistance (HIVDR) to dolutegravir is essential. We describe the prevalence and patterns of HIVDR among CLHIV on DBR with confirmed virological failure (viral load [VL] twice ≥1000 copies/mL).
Methods
We randomly selected 19 of the 25 highest‐volume ART health facilities in Malawi for participant enrolment between July 2022 and February 2023. Enrolment criteria included CLHIV aged 2–14 years, on a DBR for ≥9 months and VL ≥1000 copies/mL. Sanger HIVDR genotyping was performed if a repeat VL result post‐intensive adherence counselling was ≥1000 copies/mL. The Stanford University HIVDR Database was used for drug resistance interpretation. We present weighted HIVDR prevalence estimates with 95% confidence limits accounting for correlation within clinics.
Results
Of 302 CLHIV enrolled, 133 (44%) had confirmed virological failure. The weighted prevalence of dolutegravir resistance among CLHIV with confirmed virological failure was 15.6% (95% CI: 7.1−24.0%), with the presence of major dolutegravir drug resistance mutations (DRMs) in 14.2% (95% CI: 4.8−23.6). The most common dolutegravir DRMs were R263K ( n = 11) and G118R ( n = 4). Weighted prevalence rates of resistance to nucleoside reverse transcriptase inhibitors (NRTIs), non‐nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors were 42.2%, 65.5% and 5.0%, respectively. Three children had HIVDR to all four drug classes.
Conclusions
Dolutegravir resistance was found in nearly one in six Malawian CLHIV with confirmed virological failure on DBRs. This raises concerns for treatment options in this vulnerable population, given the coexistence of high prevalence of resistance to NRTIs and NNRTIs. These results point to the need for regular HIVDR surveillance and further research to guide genotyping prioritization and next‐line treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Public Health Institute of Malawi, Ministry of Health, Lilongwe, Malawi.
- International Training and Education Centre for Health, University of Washington, Lilongwe, Malawi.
- Division of Global HIV & TB, U.S. Centers for Disease Control and Prevention, Lilongwe, Malawi.
- Division of Global HIV & TB, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Partners in Hope, Lilongwe, Malawi.
- Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
ORCID-Profile: Alinune N Kabaghe
Förderung
- CDC HHS
- Centers for Disease Control and Prevention
Zitieren
APA
Bello, G., Kabaghe, A. N., Pals, S., Kalata, N. L., Bighignoli, B., van Oosterhout, J. J., Mkungudza, J., Agyemang, E., Zheng, D. P., Panja, L., Matola, W. B., Chitenje, M., Kampira, E., Zeh, C., Mvula, B., Alvarez, B., Kagoli, M., Mzumara, W., Simon, K. R., …, & For Malawi HIV Drug Resistance Surveillance Team (2026). Emerging Dolutegravir Resistance Among Children on Antiretroviral Therapy With Virological Failure in Malawi: Results From a 2023 National Cross‐Sectional Survey. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.70108
Vancouver
Bello G, Kabaghe AN, Pals S, Kalata NL, Bighignoli B, van Oosterhout JJ, et al. Emerging Dolutegravir Resistance Among Children on Antiretroviral Therapy With Virological Failure in Malawi: Results From a 2023 National Cross‐Sectional Survey. Journal of the International AIDS Society. 2026. doi:10.1002/jia2.70108
BibTeX
@article{Bello2026,
author = {Bello, George and Kabaghe, Alinune N and Pals, Sherri and Kalata, Newton L and Bighignoli, Barbara and van Oosterhout, Joep J and Mkungudza, Jonathan and Agyemang, Elfriede and Zheng, Du-Ping and Panja, Louis and Matola, Wilson Bilaal and Chitenje, Moses and Kampira, Elizabeth and Zeh, Clement and Mvula, Benard and Alvarez, Bianca and Kagoli, Matthews and Mzumara, Wongani and Simon, Katherine R and Namakhoma, Ireen and O'Malley, Gabrielle and Chipeta, Sikhona and Nyirenda, Rose and da Silva, Juliana and Wadonda, Nellie and For Malawi HIV Drug Resistance Surveillance Team, For Malawi HIV Drug Resistance Surveillance Team},
title = {Emerging Dolutegravir Resistance Among Children on Antiretroviral Therapy With Virological Failure in Malawi: Results From a 2023 National Cross‐Sectional Survey},
journal = {Journal of the International AIDS Society},
year = {2026},
doi = {10.1002/jia2.70108}
}
EUVIMED